Curso 2022-23
El inicio de las clases es el 5 de septiembre. En principio, la modalidad de impartición de las clases será presencial.
Acto inaugural MUIB
- Fecha y lugar: Lunes 5, 17:00, Salón de Grados, ETSIT-UPM
- Prof. Enrique J. Gómez Aguilera, Coordinador del Máster Universitario en Ingeniería Biomédica y Prof. Manuel Sierra, Director de la ETSIT-UPM.
- Conferenciante invitado: D.Manuel Marina Breysse, Cardiologist, co-founder & CEO at IDOVEN
- Título de la conferencia: “Personal learnings from creating a startup focused on AI-powered tools and services to transform cardiac diagnosis and care”
Dr. Manual Marina Breysse
CARDIOLOGIST, CHIEF EXECUTIVE OFFICER AND CO-FOUNDER AT IDOVEN
Dr. Manuel Marina Breysse is a cardiologist, CEO and co-founder of IDOVEN, a health technology company advancing early detection and precision medicine for cardiovascular diseases by creating an artificial intelligence platform. Manuel and his co-founders started IDOVEN in 2018 after conducting basic and translational research at the National Center for Cardiovascular Research (CNIC) in Spain focused on machine learning applied to cardiology.
As a cardiologist, Manuel is specialized in basic arrhythmias and high-performance sports cardiology. He has been a doctor of the Olympic athletes at the Spanish Agency for Health Protection in Sports (AEPSAD). He is also a member of the European Society of Cardiology, an Associate Partner of the Spanish Society of Cardiology, and scientist at the Cardiovascular Disease Network Biomedical Research Center (CIBERCV). Manuel has received a MS in Statistics from the University of Cordoba and MD from the University of Alcalá.
Manuel has extensive experience in R&D of new software measurement tools in the field of cardiology and in the design of clinical studies on cardiovascular diseases: the main cause of death in the world and the one that supposes the highest cost for the global health system. He is a scientist with a background in basic and translational cardiovascular research. He speaks 4 languages and is co-author of 23 scientific articles, some of them published in high-impact journals, 41 book chapters and more than 130 communications at national and international conferences.
As founder and CEO of a startup, he has achieved, together with his team, 2 Seals of Excellence from the European Commission, Horizon 2020 funding (the largest Research and Innovation program in the EU) as a member of the MAESTRIA consortium financed with €14M of H2020 funds, and €6.5M of the prestigious EIC Accelerator. IDOVEN was ranked as the number 1 Spanish HealthTech company in 2020 by NEOTEC (granted with €250.000), a program of the Spanish Center for Industrial Technological Development (CDTI). IDOVEN is generating employment, currently doubling the size of its highly talented team. The company is selling its technology to world leading HealthTech and big pharma companies. IDOVEN has attracted more than €21M in funding from some of the best Ventura Capital firms in the world: Insight Partners, Northzone and Accel starters. IDOVEN is also supported by EIT Health (EIT Health is a network of the best health innovators backed by the European Union). Manuel won the Entrepreneur XXI award from CaixaBank and ENISA in 2020 and was named by the Forbes list as one of the 100 most creative Spaniards in the business world. The company won the Healthy Longevity Catalyst Award from the US National Academy of Medicine and was honored at South Summit 2021 as Most Disruptive Startup and Best Health and Wellness Startup competing with more than 3,800 companies worldwide.
